Strategic Collaborations InvIOs is pursuing external collaborations in immuno-oncology, notably with the Dana-Farber Cancer Institute on glioblastoma and a formal Scientific Advisory Board to accelerate growth. This creates opportunities for pharma and biotech partners to pursue co-development or licensing around solid tumor and immuno-oncology programs.

Early Stage Focus The company centers on discovery and preclinical development with a clear path to clinical trials, making it an attractive partner for early-stage asset licensing, co-development, or research partnerships to de-risk new immuno-oncology programs.

Financial Readiness Recent Series A funding and overall support signal capacity to advance milestones, enabling structured partnerships with upfront and milestone payments and shared risk in collaborative programs.

Glioblastoma Focus The glioblastoma focus and immune-activation approach, paired with collaborations like Dana-Farber, positions invIOs to attract licensing or collaboration deals around GBM assets such as INV501, leveraging their preclinical capabilities.

European Access Vienna-based operations with a mid-sized team and in-house R&D, clinical development, CMC, IP and scouting create an accessible base for EU partnerships, CRO collaborations, and access to regional funding and ecosystem networks.